Subgroup of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) benefitted from the addition of necitumumab to gemcitabine plus cisplatin.
CRS-207 plus chemotherapy demonstrated encouraging clinical activity in patients with malignant pleural mesothelioma.
Osimertinib is efficacious for the first-line treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).
Updated data from a phase 1 cohort and a pooled analysis of 2 phase 2 trials demonstrated that osimertinib therapy resulted in a high overall response rate.
Durvalumab plus demonstrated encouraging activity with favorable tolerability in non-small cell lung cancer (NSCLC).
Type of chemotherapy regimen for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) does not influence who will develop brain metastases.
Despite Encouraging Activity of Osimertinib + Durvalumab, Safety Profile Warrants Further InvestigationApril 14, 2016
Osimertinib in combination with durvalumab demonstrated encouraging clinical activity, but the combination was associated with high rates of toxicities.
Select serum cytokines may be associated with survival benefit in patients with advanced refractory squamous non-small cell lung cancer (NSCLC).
Maintenance therapy with bevacizumab plus pemetrexed improved progression-free survival compared with pemetrexed alone.
Treatment with nab-paclitaxel plus carboplatin resulted in significant improvement in objective response rate and overall survival.
Ceritinib treatment demonstrated clinically meaningful whole body and intracranial activity with an acceptable tolerability profile.
Brigatinib demonstrated antitumor activity in crizotinib-treated and crizotinib-naïve patients with non-small cell lung cancer (NSCLC).
The addition of gefitinib to first-line pemetrexed plus carboplatin prolongs progression-free survival compared with chemotherapy alone and gefitinib alone.
Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.
BI 1482694 demonstrated meaningful clinical activity in patients with EGFR TKI-resistant non-small cell lung cancer (NSCLC).
Patients with clinically diagnosed early-stage lung cancer were found to have improved cancer-specific survival.
Different EGFR mutation subtypes are associated with different clinical and demographic characteristics.
Afatinib significantly prolonged progression-free survival (PFS) for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy